Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(33.3%)

Phase 3

2(33.3%)

Phase 2

2(33.3%)

6Total

N/A(2)

Phase 3(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04320979Phase 3Active Not Recruiting

Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients

Role: collaborator

NCT06498154Phase 2Recruiting

Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Role: collaborator

NCT07162519Not ApplicableNot Yet Recruiting

Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients

Role: collaborator

NCT03955367Phase 3Unknown

Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer

Role: collaborator

NCT03579979Not ApplicableCompleted

Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG

Role: collaborator

NCT02621333Phase 2Terminated

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Role: collaborator

All 6 trials loaded